Fidaxomicin denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for fidaxomicin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step Therapy to Fidaxomicin — and How to Overcome It

Step therapy (sometimes called "fail-first") requires patients to try one or more less expensive antibiotics before UnitedHealthcare will approve fidaxomicin. For Clostridioides difficile infection, this typically means the plan requires documented prior use of another agent in the same therapeutic category. Because CDI can recur and because antibiotic selection affects recurrence risk, many patients arrive with a legitimate clinical reason why the stepped agent is not appropriate — making these denials very worth contesting.

Many states have enacted step-therapy override laws that require insurers to grant exceptions when a required prior-step agent is clinically contraindicated, previously failed, or would cause harm. Check whether your state's protections apply to your plan type.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full-and-fair review of any adverse benefit determination. File within the timeframe on your denial notice.
• External review: Independent external review is available after internal appeal exhaustion. The window to request external review is generally approximately four months from the original denial.
• Expedited track: Active, severe, or recurrent CDI typically qualifies as an urgent condition. Request expedited review to get a decision within 72 hours.

## Documentation Categories to Gather

1. Diagnosis and severity — documented diagnosis of CDI, episode history (number of recurrences, dates, severity per clinician notes), and any hospitalization records. 2. Prior-step treatment history — if you already tried and failed the required agent, provide dates, doses as recorded in the chart, outcomes, and the reason treatment was stopped or failed. 3. Clinical exception basis — if you have not yet tried the required agent, your prescriber must explain why that agent is clinically inappropriate for you specifically (e.g., prior adverse reaction, documented resistance pattern, or recurrence history that supports fidaxomicin per applicable guideline). 4. Prescriber medical-necessity letter — should reference the FDA-approved prescribing label for fidaxomicin and the relevant infectious disease society guideline (e.g., IDSA/SHEA) generically, explaining the clinical rationale without needing to reproduce numeric statistics.

## Criteria-Mapping Structure

Request UHC's published step-therapy coverage policy for fidaxomicin. Then build a response grid:

| Step-Therapy Requirement | Your Chart Evidence | |---|---| | Required prior agent(s) identified | [List agents from policy] | | Prior trial or clinical exception basis | [Chart note / prescriber letter date] | | Diagnosis confirmed | [Lab/chart note date] | | Episode history documented | [Dates of prior episodes] |

Answer each row with specific chart facts. Attach the FDA prescribing label and the prescriber's letter. A concise, well-organized appeal package addressing each criterion point-by-point is the strongest approach.